LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Arrowhead Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

16.78 2.13

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

16.45

Max

17.09

Schlüsselkennzahlen

By Trading Economics

Einkommen

546M

370M

Verkäufe

540M

543M

EPS

2.75

Gewinnspanne

68.258

Angestellte

609

EBITDA

554M

405M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+138.94% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

167M

2.3B

Vorheriger Eröffnungskurs

14.65

Vorheriger Schlusskurs

16.78

Nachrichtenstimmung

By Acuity

79%

21%

359 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Arrowhead Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Sept. 2024, 10:38 UTC

Wichtige Markttreiber

Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran

Peer-Vergleich

Kursveränderung

Arrowhead Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

138.94% Vorteil

12-Monats-Prognose

Durchschnitt 39.33 USD  138.94%

Hoch 80 USD

Tief 17 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Arrowhead Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

12 ratings

7

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

11.5 / 12.23Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

359 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.